View Future GrowthThis company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsMural Oncology 과거 순이익 실적과거 기준 점검 0/6Mural Oncology의 연간 평균 수익은 11.8%였으며, Biotechs 산업의 수익은 연간 37.7% 증가했습니다.핵심 정보11.83%순이익 성장률18.83%주당순이익(EPS) 성장률Biotechs 산업 성장률17.04%매출 성장률n/a자기자본이익률-215.81%순이익률n/a최근 순이익 업데이트30 Sep 2025최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • Dec 06+ 5 more updatesMural Oncology plc(NasdaqGM:MURA) dropped from Russell 3000E Value BenchmarkMural Oncology plc(NasdaqGM:MURA) dropped from Russell 3000E Value Benchmark공고 • Dec 05+ 1 more updateXOMA Royalty Corporation (NasdaqGM:XOMA) completed the acquisition of Mural Oncology plc (NasdaqGM:MURA) from group of shareholders.XOMA Royalty Corporation (NasdaqGM:XOMA) proposed to acquire Mural Oncology plc (NasdaqGM:MURA) from group of shareholders on June 9, 2025. XOMA Royalty Corporation entered into a definitive agreement to acquire Mural Oncology plc from group of shareholders for $36.2 million on August 20, 2025. A cash consideration valued at $2.035 per share will be paid by XOMA Royalty Corporation for 17.324771 million shares. XOMA Royalty Corporation will pay additional cash amount per share of up to $0.205 for $3.56 million in cash. Pursuant to the terms of the Transaction Agreement and subject to certain conditions and the closing of the Acquisition shareholders (i) are entitled to receive a base cash price of $2.035 per share, which has been calculated on the basis of the Company having approximately $36.2 million of closing net cash and is payable to the Company’s shareholders at the Closing regardless of the actual amount of the Company’s closing net cash on or before the Closing, and (ii) may receive an additional cash amount per share of up to $0.205. The Consideration payable under the terms of the Acquisition will be funded by XOMA Royalty’s existing cash and cash equivalent resources. The transaction is subject to approval of offer by target shareholders, subject to antitrust regulations, all required Clearances of any Governmental Entity and subject to sanction of the Irish High Court. The transaction has been approved by board of Mural Oncology and XOMA Royalty. The transaction is expected to close in fourth quarter of 2025. On October 24, 2025, the shareholders of Mural Oncology plc has approved the transaction. As of November 26, 2025, the transaction is expected to close in early December 2025. Lucid Capital Markets, LLC acted as financial advisor and fairness opinion provider to Mural Oncology plc and and will be paid a fee of $0.45 million. Ryan A. Murr and Branden C. Berns of Gibson, Dunn & Crutcher LLP acted as legal advisor for XOMA Royalty Corporation. Justin McKenna and Anne Harkin of Mason Hayes & Curran Solicitors acted as legal advisor for XOMA Royalty Corporation. Christopher McLaughlin and David Vos of Arthur Cox LLP acted as legal advisor for Mural Oncology plc. Stuart M. Falber, Mark Nylen and Scott Lunin of Wilmer Cutler Pickering Hale and Dorr LLP acted as legal advisor for Mural Oncology plc. MacKenzie Partners, Inc. acted as information agent/proxy solicitor to Mural Oncology plc and will be paid a fee of $0.01 million. XOMA Royalty Corporation (NasdaqGM:XOMA) completed the acquisition of Mural Oncology plc (NasdaqGM:MURA) from group of shareholders December 4, 2025. On December 3, 2025, the High Court sanctioned the Scheme.공고 • Aug 20XOMA Royalty Corporation (NasdaqGM:XOMA) entered into a definitive agreement to acquire Mural Oncology plc (NasdaqGM:MURA) for $35.3 million.XOMA Royalty Corporation (NasdaqGM:XOMA) proposed to acquire Mural Oncology plc (NasdaqGM:MURA) on June 9, 2025. XOMA Royalty Corporation entered into a definitive agreement to acquire Mural Oncology plc for $35.3 million on August 20, 2025. A cash consideration valued at $2.035 per share will be paid by XOMA Royalty Corporation for 17.324771 million shares. XOMA Royalty Corporation will pay an earnout/contingent payment of $3.56 million cash. Pursuant to the terms of the Transaction Agreement and subject to certain conditions and the closing of the Acquisition shareholders (i) are entitled to receive a base cash price of $2.035 per share, which has been calculated on the basis of the Company having approximately $36.2 million of closing net cash and is payable to the Company’s shareholders at the Closing regardless of the actual amount of the Company’s closing net cash on or before the Closing, and (ii) may receive an additional cash amount per share of up to $0.205. The Consideration payable under the terms of the Acquisition will be funded by XOMA Royalty’s existing cash and cash equivalent resources. The transaction is subject to approval of offer by target shareholders, subject to antitrust regulations, all required Clearances of any Governmental Entity and subject to court approval. The transaction has been approved by board of Mural Oncology and XOMA Royalty. The transaction is expected to close in fourth quarter of 2025. Lucid Capital Markets, LLC acted as financial advisor for Mural Oncology plc. Gibson, Dunn & Crutcher LLP acted as legal advisor for XOMA Royalty Corporation. Mason Hayes & Curran Solicitors acted as legal advisor for XOMA Royalty Corporation. Christopher McLaughlin and David Vos of Arthur Cox LLP acted as legal advisor for Mural Oncology plc. Stuart M. Falber, Mark Nylen and Scott Lunin of Wilmer Cutler Pickering Hale and Dorr LLP acted as legal advisor for Mural Oncology plc.분석 기사 • Aug 05Mural Oncology (NASDAQ:MURA) Will Have To Spend Its Cash WiselyNasdaqGM:MURA 1 Year Share Price vs Fair Value Explore Mural Oncology's Fair Values from the Community and select yours...공고 • Apr 29Mural Oncology plc, Annual General Meeting, Jun 11, 2025Mural Oncology plc, Annual General Meeting, Jun 11, 2025. Location: arthur coxllpat ten earlsfort terrace, d02 t380, ireland, dublin 2 United States공고 • Apr 16Mural Oncology plc Announces Reduction in WorkforceOn April 14, 2025, the board of directors of Mural Oncology plc determined to discontinue all clinical development of nemvaleukin alfa and, in connection with such decision, approved a reduction in the Company’s workforce by approximately 104 positions, or approximately 90%. The Company expects to substantially complete the Reduction by the end of the second quarter of 2025. The Company expects to incur costs of approximately $9.0 million to $10.0 million related to the Reduction, primarily consisting of severance payments and employee benefit costs. Additionally, the Company expects to incur $2.0 million to $4.0 million in non-cash impairment charges associated with property and equipment expected to be sold or otherwise disposed of. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the Reduction. The costs related to the Reduction are expected to be substantially incurred in the second quarter of 2025. The estimated costs that the Company expects to incur and the estimated timing to complete the Reduction and for the incurrence of the costs are subject to a number of assumptions, and actual results may differ materially from these estimates.공고 • Apr 15Mural Oncology plc Announces Plans to Explore Strategic AlternativesMural Oncology plc announced that following review of data from its phase 2 ARTISTRY-6 trial in melanoma and previously announced results from the phase 3 ARTISTRY-7 trial in platinum-resistant ovarian cancer, the company is discontinuing all clinical development of nemvaleukin alfa and plans to immediately commence the exploration of strategic alternatives focused on maximizing shareholder value. Mural has engaged Lucid Capital Markets, LLC to act as its financial advisor in connection with the exploration of strategic alternatives. The company had approximately $144.4 million of cash, cash equivalents, and marketable securities as of December 31, 2024. In conjunction with today's announcement, Mural plans to reduce its workforce by approximately 90%. ARTISTRY-6, cohort 2 is a phase 2, single-arm trial evaluating nemvaleukin as a monotherapy in 92 patients with mucosal melanoma with a minimum follow-up of at least six months. A review of the topline data from this cohort showed that the primary endpoint was not achieved. Mural also conducted a review of preliminary data from ARTISTRY-6, cohorts 3, evaluating less-frequent intravenous dosing of nemvaleukin in patients with cutaneous melanoma, and did not observe a level of activity that warranted continuation. Based on the totality of these data, together with the interim overall survival results from ARTISTRY-7 as announced on March 25, 2025, Mural will discontinue all clinical development of nemvaleUKin. Mural plans to explore potential strategic alternatives including, but not limited to, an offer for or other acquisition of the company, merger, business combination, or other transaction. While the company has not set a timeline for completion of this process, further updates and developments will be disclosed as appropriate or where necessary under regulatory requirements. There can be no assurance that the exploration of strategic alternatives will result in the company pursuing a transaction or that any acquisition or other transaction involving the company will be completed, nor as to the terms on which any acquisition or other transaction will occur, if at all. The company confirms that, as at the date of this announcement, it is not in receipt of any approaches and not in active discussions with any potential offeror. Mural is subject to the Irish Takeover Panel Act, 1997, Irish Takeover Rules 2022 (the " Irish Takeover Rules"), which have certain implications on some of the strategic alternatives to be explored by the company. As the exploration of strategic alternatives is expected to include consideration of potential offers for the company, following the publication of this announcement Mural is now considered to be in an " offer period" as defined in the Irish Takeover Rules and the dealing disclosure requirements of Rule 8 of the Irish Takeover Rules as summarized below will apply. The Irish Takeover Panel has granted a dispensation from the requirements of Rules 2.4(b) and 2.4(c) of the Irish Takeover Rules such that any potential offeror will not be required to be publicly identified as a result of this announcement for so long as the strategic evaluation is ongoing. Such parties should nonetheless be mind of their obligations under the Irish Takeover Rules, including in particular with respect to confidentiality under Rule 2.1 and the circumstances in which an announcement may be required under Rule 2.2. If a potential offeror has any doubt about its obligations pursuant to the Irish Takeover Rules, it should contact its financial adviser(s) and, where applicable, it should also consult with the Irish Takeover Panel. This is an announcement under Rule 2.4 of the Irish Takeover Rules and is not an announcement of a firm intention by any party to make an offer under Rule 2.7 of the Irish Takeover Rules.Seeking Alpha • Mar 28Mural Oncology: Phase 3 Clinical Trial Setback Undermines Company's Future ProspectsSummary Mural Oncology's stock plummeted 57% after halting the Phase 3 ARTISTRY-7 trial for nemvaleukin alfa, which failed to show significant overall survival benefits in PROC. The trial's failure delays any potential NDA submission, impacting the commercial viability of nemvaleukin alfa and raising concerns about its efficacy in other indications. Upcoming data from the Phase 2 ARTISTRY-6 trial for mucosal melanoma is crucial, but recent setbacks cast doubt on nemvaleukin alfa's overall prospects. Concerns about cash burn and potential dilutive capital raises further dampen our investment outlook, leading us to avoid investing in Mural Oncology. Read the full article on Seeking Alpha공고 • Mar 25Mural Oncology plc Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with Keytruda®? (Pembrolizumab) in Patients with Platinum-Resistant Ovarian CancerMural Oncology plc announced that the ARTISTRY-7 phase 3 trial of nemvaleukin alfa in combination with Merck's (known as MSD outside the US and Canada) anti-PD-1 therapy, KEYTRUDA®? (pembrolizumab) versus investigator's choice chemotherapy in patients with platinum-resistant ovarian cancer (PROC) will not continue to final analysis and the company will cease development of nemvaleukin for PROC. In the pre-specified interim analysis conducted by the independent data monitoring committee, nemvaleukin in combination with pembrolizumab did not achieve a statistically significant improvement in overall survival versus investigator's choice chemotherapy alone and the company believes the study is highly unlikely to achieve success at the final analysis. Median overall survival was 10.1 months for patients treated with nemvaleukin in combination With pembrolizumab and 9.8 months for patients treated with investigator's choice chemotherapy (hazard ratio: 0.98). There has been a great deal of work across the industry in this immunologically cold tumor, yet there are still few treatment options that improve survival in this very difficult-to-treat tumor type. Nemvaleukin has a well characterized and favorable safety profile, both as a monotherapy and in combination with pembrolIZumab, with over 800 patients treated across the broader clinical program. Preliminary data readouts for less-frequent intravenous dosing of nemvaleukin in patients with cutaneous melanoma are expected in the second quarter of 2025 for cohort 3 of ARTISTRY-6 (monotherapy) and the second half of 2025 for cohort 4 of ARTISTRY-6 ("combination therapy), subject to patient enrollment.공고 • Mar 12Mural Oncology plc has filed a Follow-on Equity Offering in the amount of $75 million.Mural Oncology plc has filed a Follow-on Equity Offering in the amount of $75 million. Security Name: Ordinary Shares Security Type: Common Stock Transaction Features: At the Market Offering분석 기사 • Nov 26Here's Why We're Watching Mural Oncology's (NASDAQ:MURA) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...공고 • Nov 13Mural Oncology plc Provides Update on Pipeline ProgressMural Oncology plc's late-stage trials of nemvaleukin alfa (nemvaleukin), an engineered fusion protein designed to leverage Interleukin-2’s (IL-2) antitumor effects while mitigating its hallmark toxicities, remain on track. The company shared new information related to study design, statistical assumptions, and study execution at a virtual Investor Day in September 2024, including: Completion of enrollment in ARTISTRY-7, the company’s potentially registrational phase 3 trial in platinum-resistant ovarian cancer (PROC), with a total of 456 patients enrolled. The study is comparing the combination of nemvaleukin and pembrolizumab versus investigator’s choice single agent chemotherapy. Mural expects to report interim overall survival (OS) results in late FIRST QUARTER OF or early SECOND QUARTER OF based on an analysis performed at approximately 75% of OS events. If the hazard ratio meets the bar for success (0.727, or a 27.3% reduction in the risk of death assuming exactly 215 OS events), the company plans to file a Biologics License Application (BLA) in 2025 subject to discussions with the U.S. Food and Drug Administration (FDA). The company expects to report final results in the second quarter of 2026. · Completion of enrollment in ARTISTRY-6, Cohort 2, the company’s potentially registrational phase 2 study of single agent nemvaleukin in patients with unresectable or metastatic mucosal melanoma, with 92 patients enrolled. Mural anticipates reporting top-line results from cohort 2 of ARTISTRY-6 in SECOND QUARTER Of 2025. The target response rate is 25%. Mural believes that in this rare and highly aggressive tumor with poor outcomes even in the first line setting, demonstrating durable responses with a response rate of 20-25% would be meaningful for patients, and would support a discussion with the FDA regarding a BLA submission and potential accelerated approval. Mural is also evaluating a less-frequent intravenous (LFIV) dose of nemvaleukin in patients with cutaneous melanoma in ARTISTRY-6, Cohort 3 (monotherapy) and Cohort 4 (combination with pembrolizumab). The company continues to expect preliminary data readouts in the monotherapy cohort in the first half of 2025, and in the combination cohort in the second half of 2025. Mural plans to nominate development candidates for its IL-18 and IL-12 programs by the end of 2024. The company expects to submit an Investigational New Drug (IND) Application for its IL-18 program to the FDA in fourth quarter of 2025.공고 • Nov 08Mural Oncology Presents Clinical and Preclinical Data Across Its Pipeline At the 39Th Annual Meeting of the Society for Immunotherapy of CancerMural Oncology plc shared three poster presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer, taking place November 6-10, 2024 in Houston. Data presented from the ARTISTRY-3 clinical trial of Mural’s lead candidate, nemvaleukin alfa (nemvaleukin), showed tumor site-specific pharmacodynamic activity and immune activation in patients with ovarian cancer and mucosal melanoma. In addition, Mural presented preclinical data from its interleukin (IL)-12 and IL-18 programs that supported the company's unique protein engineering capabilities to overcome shortcomings associated with cytokines. Tumor microenvironment pharmacodynamic effect of nemvaleukin less frequent intravenous dosing in multiple solid tumors: results from the phase 1/2 ARTISTRY-3 study: Nemvaleukin is a novel, engineered fusion protein designed to leverage antitumor effects of the IL-2 pathway while mitigating the hallmark toxicities that have historically limited its use. ARTISTRY-3, a phase 1/2 study, evaluated less frequent intravenous dosing of nemvaleukin in advanced solid tumors. Paired biopsies were available from 8 patients across the three different dosing schedules of nemvaleukin. Collectively, LFIV nemvaleukin demonstrated tumor-site-specific pharmacodynamic activity and immune activation. Nemvaleukin treatment increased cytolytic NK and CD8 T cell densities in the tumor microenvironment. Density ratios of CD8 and NK cells relative to immune-suppressive Tregs were also favorable for the nemvaleukin LFIV regimen. The results were seen in biopsies from both mucosal melanoma and ovarian cancer tumors, supporting the hypothesis that nemvaleukin has the potential to recruit cytolytic effectors to poorly immunogenic tumor sites. Mural is currently running two late-stage, potentially registrational trials in platinum-resistant ovarian cancer (ARTISTRY-7) and mucosal melanoma (ARTISTRY-6, cohort 2), with data readouts expected in late Q1/early Second Quarter 2025 and Second Quarter 2025, respectively. Preclinical efficacy and immune activity of half-life extended IL-18 fusion proteins resistant to IL-18BP suppression. IL-18 is a potent immune-stimulating cytokine, but it is limited by IL-18 binding protein (IL-18BP), a secreted high-affinity decoy receptor that neutralizes IL-18, thus limiting its activity over time. Mural’s protein engineering aims to address the shortcomings of native IL-18 in two ways. First through the introduction of mutations designed to minimally impact the native structure while eliminating binding to IL-18BP. Secondly, by extending the half-life of IL-18BP via fusion to a protein scaffold to increase the cytokine’s exposure, allowing for sustained immune stimulation. In preclinical models, a weekly dosing regimen in mice provided durable immune responses and tumor growth inhibition. These mouse ortholog variants demonstrated resistance to IL-18BP and increased half-life, with durable expansion of immune-stimulating NK and CD8 T cells. These studies support pursuit of IND-enabling studies for first-in-human clinical trials. Mural plans to nominate a development candidate for its IL-18 program by the end of 2024 and intends to submit an Investigational New Drug (IND) Application to the FDA in Fourth Quarter 2025. Modulation of IL-12p70 exposure and activity following sequential administration of tumor targeted self-assembling split IL-12 subunits. IL-12p70 is a potent stimulator of the immune system with profound anti-tumor activity but very poor tolerability. Mural is developing an innovative approach to mitigate that toxicity by creating inactive split IL-12 subunits (IL-12p35 and IL-12p40) and assembling functional IL-12p70 predominantly in the tumor and tumor microenvironment. In murine models, increasing the interval time between subunit injections or reducing the dose level of the second subunit effectively modulated serum drug concentration while maintaining IL-12 levels in the tumor. Pharmacokinetics and pharmacodynamics were also assessed in non-human primates, where the inactive subunits were assembled and formed functional IL-12p70 in the periphery. Together, these data suggest Mural’s novel approach may unlock the potential of IL-12p70 as a therapeutic by mitigating the toxicity associated with systemic administration. Mural plans to nominate a development candidate for its IL-12 program by the end of 2024.공고 • Sep 24Mural Oncology plc Appoints Sachiyo Minegishi to its Board of DirectorsMural Oncology plc announced the appointment of Sachiyo Minegishi to its board of directors, effective September 20, 2024. Ms. Minegishi will serve as Chair of the Audit Committee and will also be joining the company's Nominating and Corporate Governance Committee. With over 20 years of industry experience, Sachiyo brings a successful record of helping companies navigate through important clinical, financial, and corporate milestones. Sachiyo brings over two decades of biopharma experience, with a focus on corporate strategy, finance, development, and commercialization. She is currently the Chief Operating Officer at Rectify Pharmaceuticals, driving corporate and financing strategy to advance its lead program from discovery to clinical stage. Prior to Rectify, Sachiyo was Chief Financial Officer at Akouos Inc., where she led corporate finance and business development strategy and played a key role in the acquisition of the company by Eli Lilly. Before that, she was a Global Program Lead at bluebird bio, where she led a team to execute global development and commercialization strategy for a portfolio of gene therapies for sickle cell disease. Sachiyo has also held leadership roles that helped accelerate corporate growth at Human Genome Sciences, Genzyme, and Amgen.공고 • Aug 01Mural Oncology plc Announces the Appointment of George Golumbeski to its Board of DirectorsMural Oncology plc announced the appointment of George Golumbeski, Ph.D., to its board of directors effective July 30. Dr. Golumbeski has extensive experience with strategic collaborations, M&A, in-licensing, out-licensing, and alliance management. He currently serves as a partner in DROIA Ventures, a specialist biotech investment firm focused on therapeutics for oncology and genetic disease. He previously served as President and Head of Corporate Development for GRAIL where he led corporate collaborations and served as an advisor to the CEO. Prior to GRAIL, Dr. Golumbeski was Executive Vice President of Business Development for Celgene (now a Bristol Myers Squibb company) where over his nine-year tenure he developed new models for corporate collaborations to drive corporate growth. He has also held leadership roles at Nabriva Therapeutics, Novartis Oncology, and Elan Biopharmaceuticals.분석 기사 • Jul 17Here's Why We're A Bit Worried About Mural Oncology's (NASDAQ:MURA) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...공고 • Jul 03Mural Oncology plc(NasdaqGM:MURA) dropped from Russell 3000 IndexMural Oncology plc(NasdaqGM:MURA) dropped from Russell 3000 Index공고 • Apr 14Mural Oncology plc, Annual General Meeting, May 30, 2024Mural Oncology plc, Annual General Meeting, May 30, 2024, at 13:00 Coordinated Universal Time. Location: Arthur Cox LLP at Ten Earlsfort Terrace, Dublin 2, D02 T380 Ireland Agenda: To elect, by separate resolutions, the five director nominees named in this proxy statement to the board of directors, to serve until the Company’s 2025 annual general meeting; to ratify, in a non-binding advisory vote, the selection of PricewaterhouseCoopers LLP as the Company’s independent auditor for the fiscal year ending December 31, 2024 and to authorize, in a binding vote, the board of directors, acting through the audit committee, to set the independent auditor’s remuneration; and to consider and act on such business as may properly come before the AGM or any adjournment or postponement thereof.분석 기사 • Mar 28We're Keeping An Eye On Mural Oncology's (NASDAQ:MURA) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Seeking Alpha • Mar 04Recent Spin Mural Oncology At An Attractive Discount To Cash And Portfolio ValueSummary Mural Oncology trades at approximately $5, a material discount to cash holdings of over $16/share, as reported in November 2023. The pipeline of 3 major candidates of cytokine cancer therapies at different stages in clinical trials may offer material value if things go well. As a spin-off since November 2023, Mural may receive investor attention in 2024 as it starts to attend industry conferences and releases financial reports. Still, this is a risky and illiquid biotech small cap that could go to zero if trial results are poor or for other reasons. Read the full article on Seeking Alpha공고 • Jan 09Mural Oncology plc Announces Enhancements to Late-Stage Clinical TrialsMural Oncology plc announced strategic changes to its ARTISTRY-6 and ARTISTRY-7 clinical trials designed to generate more meaningful clinical data for these late-stage, potentially registrational trials of nemvaleukin. These changes are as follows: Cohort 2 of ARTISTRY-6 is a potentially registrational, phase 2 trial evaluating nemvaleukin as a monotherapy in mucosal melanoma patients. Together have been thinking critically about the best ways to deliver treatments to patients who desperately need them. The company believe expanding patient enrollment in both potentially registrational trials, as well as shifting the primary endpoint of the ARISTRY-7 trial, may result in more meaningful clinical data. Now led by an experienced and highly accomplished oncology-focused executive team and board of directors, the company is leveraging its core competencies in immune cell modulation and protein engineering. Mural's lead product candidate, nemvaleukin, is being developed to treat a wide range of solid tumors. Mural is also advancing engineered therapies targeting interleukin-18 and interleukin-12, with plans to nominate development candidates for each program in 2024. The Company's cash resources of $275 million, as of November 15, 2023, are expected to fund its operations into fourth quarter 2025.매출 및 비용 세부 내역Mural Oncology가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이NasdaqGM:MURA 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비30 Sep 250-119376830 Jun 250-147389831 Mar 250-1313710231 Dec 240-1293810030 Sep 240-1544611530 Jun 240-1734512831 Mar 240-1924414231 Dec 230-2074115530 Sep 230-1963015530 Jun 230-1962916031 Mar 230-1912815731 Dec 220-19028157양질의 수익: MURA 은(는) 현재 수익성이 없습니다.이익 마진 증가: MURA는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: MURA는 수익성이 없지만 지난 5년 동안 연평균 11.8%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 MURA의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: MURA은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(59.3%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: MURA는 현재 수익성이 없으므로 자본 수익률이 음수(-215.81%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/12/05 15:17종가2025/12/04 00:00수익2025/09/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Mural Oncology plc는 2명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Soumit RoyJonesTrading Institutional Services, LLCJudah FrommerMorgan Stanley
공고 • Dec 06+ 5 more updatesMural Oncology plc(NasdaqGM:MURA) dropped from Russell 3000E Value BenchmarkMural Oncology plc(NasdaqGM:MURA) dropped from Russell 3000E Value Benchmark
공고 • Dec 05+ 1 more updateXOMA Royalty Corporation (NasdaqGM:XOMA) completed the acquisition of Mural Oncology plc (NasdaqGM:MURA) from group of shareholders.XOMA Royalty Corporation (NasdaqGM:XOMA) proposed to acquire Mural Oncology plc (NasdaqGM:MURA) from group of shareholders on June 9, 2025. XOMA Royalty Corporation entered into a definitive agreement to acquire Mural Oncology plc from group of shareholders for $36.2 million on August 20, 2025. A cash consideration valued at $2.035 per share will be paid by XOMA Royalty Corporation for 17.324771 million shares. XOMA Royalty Corporation will pay additional cash amount per share of up to $0.205 for $3.56 million in cash. Pursuant to the terms of the Transaction Agreement and subject to certain conditions and the closing of the Acquisition shareholders (i) are entitled to receive a base cash price of $2.035 per share, which has been calculated on the basis of the Company having approximately $36.2 million of closing net cash and is payable to the Company’s shareholders at the Closing regardless of the actual amount of the Company’s closing net cash on or before the Closing, and (ii) may receive an additional cash amount per share of up to $0.205. The Consideration payable under the terms of the Acquisition will be funded by XOMA Royalty’s existing cash and cash equivalent resources. The transaction is subject to approval of offer by target shareholders, subject to antitrust regulations, all required Clearances of any Governmental Entity and subject to sanction of the Irish High Court. The transaction has been approved by board of Mural Oncology and XOMA Royalty. The transaction is expected to close in fourth quarter of 2025. On October 24, 2025, the shareholders of Mural Oncology plc has approved the transaction. As of November 26, 2025, the transaction is expected to close in early December 2025. Lucid Capital Markets, LLC acted as financial advisor and fairness opinion provider to Mural Oncology plc and and will be paid a fee of $0.45 million. Ryan A. Murr and Branden C. Berns of Gibson, Dunn & Crutcher LLP acted as legal advisor for XOMA Royalty Corporation. Justin McKenna and Anne Harkin of Mason Hayes & Curran Solicitors acted as legal advisor for XOMA Royalty Corporation. Christopher McLaughlin and David Vos of Arthur Cox LLP acted as legal advisor for Mural Oncology plc. Stuart M. Falber, Mark Nylen and Scott Lunin of Wilmer Cutler Pickering Hale and Dorr LLP acted as legal advisor for Mural Oncology plc. MacKenzie Partners, Inc. acted as information agent/proxy solicitor to Mural Oncology plc and will be paid a fee of $0.01 million. XOMA Royalty Corporation (NasdaqGM:XOMA) completed the acquisition of Mural Oncology plc (NasdaqGM:MURA) from group of shareholders December 4, 2025. On December 3, 2025, the High Court sanctioned the Scheme.
공고 • Aug 20XOMA Royalty Corporation (NasdaqGM:XOMA) entered into a definitive agreement to acquire Mural Oncology plc (NasdaqGM:MURA) for $35.3 million.XOMA Royalty Corporation (NasdaqGM:XOMA) proposed to acquire Mural Oncology plc (NasdaqGM:MURA) on June 9, 2025. XOMA Royalty Corporation entered into a definitive agreement to acquire Mural Oncology plc for $35.3 million on August 20, 2025. A cash consideration valued at $2.035 per share will be paid by XOMA Royalty Corporation for 17.324771 million shares. XOMA Royalty Corporation will pay an earnout/contingent payment of $3.56 million cash. Pursuant to the terms of the Transaction Agreement and subject to certain conditions and the closing of the Acquisition shareholders (i) are entitled to receive a base cash price of $2.035 per share, which has been calculated on the basis of the Company having approximately $36.2 million of closing net cash and is payable to the Company’s shareholders at the Closing regardless of the actual amount of the Company’s closing net cash on or before the Closing, and (ii) may receive an additional cash amount per share of up to $0.205. The Consideration payable under the terms of the Acquisition will be funded by XOMA Royalty’s existing cash and cash equivalent resources. The transaction is subject to approval of offer by target shareholders, subject to antitrust regulations, all required Clearances of any Governmental Entity and subject to court approval. The transaction has been approved by board of Mural Oncology and XOMA Royalty. The transaction is expected to close in fourth quarter of 2025. Lucid Capital Markets, LLC acted as financial advisor for Mural Oncology plc. Gibson, Dunn & Crutcher LLP acted as legal advisor for XOMA Royalty Corporation. Mason Hayes & Curran Solicitors acted as legal advisor for XOMA Royalty Corporation. Christopher McLaughlin and David Vos of Arthur Cox LLP acted as legal advisor for Mural Oncology plc. Stuart M. Falber, Mark Nylen and Scott Lunin of Wilmer Cutler Pickering Hale and Dorr LLP acted as legal advisor for Mural Oncology plc.
분석 기사 • Aug 05Mural Oncology (NASDAQ:MURA) Will Have To Spend Its Cash WiselyNasdaqGM:MURA 1 Year Share Price vs Fair Value Explore Mural Oncology's Fair Values from the Community and select yours...
공고 • Apr 29Mural Oncology plc, Annual General Meeting, Jun 11, 2025Mural Oncology plc, Annual General Meeting, Jun 11, 2025. Location: arthur coxllpat ten earlsfort terrace, d02 t380, ireland, dublin 2 United States
공고 • Apr 16Mural Oncology plc Announces Reduction in WorkforceOn April 14, 2025, the board of directors of Mural Oncology plc determined to discontinue all clinical development of nemvaleukin alfa and, in connection with such decision, approved a reduction in the Company’s workforce by approximately 104 positions, or approximately 90%. The Company expects to substantially complete the Reduction by the end of the second quarter of 2025. The Company expects to incur costs of approximately $9.0 million to $10.0 million related to the Reduction, primarily consisting of severance payments and employee benefit costs. Additionally, the Company expects to incur $2.0 million to $4.0 million in non-cash impairment charges associated with property and equipment expected to be sold or otherwise disposed of. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the Reduction. The costs related to the Reduction are expected to be substantially incurred in the second quarter of 2025. The estimated costs that the Company expects to incur and the estimated timing to complete the Reduction and for the incurrence of the costs are subject to a number of assumptions, and actual results may differ materially from these estimates.
공고 • Apr 15Mural Oncology plc Announces Plans to Explore Strategic AlternativesMural Oncology plc announced that following review of data from its phase 2 ARTISTRY-6 trial in melanoma and previously announced results from the phase 3 ARTISTRY-7 trial in platinum-resistant ovarian cancer, the company is discontinuing all clinical development of nemvaleukin alfa and plans to immediately commence the exploration of strategic alternatives focused on maximizing shareholder value. Mural has engaged Lucid Capital Markets, LLC to act as its financial advisor in connection with the exploration of strategic alternatives. The company had approximately $144.4 million of cash, cash equivalents, and marketable securities as of December 31, 2024. In conjunction with today's announcement, Mural plans to reduce its workforce by approximately 90%. ARTISTRY-6, cohort 2 is a phase 2, single-arm trial evaluating nemvaleukin as a monotherapy in 92 patients with mucosal melanoma with a minimum follow-up of at least six months. A review of the topline data from this cohort showed that the primary endpoint was not achieved. Mural also conducted a review of preliminary data from ARTISTRY-6, cohorts 3, evaluating less-frequent intravenous dosing of nemvaleukin in patients with cutaneous melanoma, and did not observe a level of activity that warranted continuation. Based on the totality of these data, together with the interim overall survival results from ARTISTRY-7 as announced on March 25, 2025, Mural will discontinue all clinical development of nemvaleUKin. Mural plans to explore potential strategic alternatives including, but not limited to, an offer for or other acquisition of the company, merger, business combination, or other transaction. While the company has not set a timeline for completion of this process, further updates and developments will be disclosed as appropriate or where necessary under regulatory requirements. There can be no assurance that the exploration of strategic alternatives will result in the company pursuing a transaction or that any acquisition or other transaction involving the company will be completed, nor as to the terms on which any acquisition or other transaction will occur, if at all. The company confirms that, as at the date of this announcement, it is not in receipt of any approaches and not in active discussions with any potential offeror. Mural is subject to the Irish Takeover Panel Act, 1997, Irish Takeover Rules 2022 (the " Irish Takeover Rules"), which have certain implications on some of the strategic alternatives to be explored by the company. As the exploration of strategic alternatives is expected to include consideration of potential offers for the company, following the publication of this announcement Mural is now considered to be in an " offer period" as defined in the Irish Takeover Rules and the dealing disclosure requirements of Rule 8 of the Irish Takeover Rules as summarized below will apply. The Irish Takeover Panel has granted a dispensation from the requirements of Rules 2.4(b) and 2.4(c) of the Irish Takeover Rules such that any potential offeror will not be required to be publicly identified as a result of this announcement for so long as the strategic evaluation is ongoing. Such parties should nonetheless be mind of their obligations under the Irish Takeover Rules, including in particular with respect to confidentiality under Rule 2.1 and the circumstances in which an announcement may be required under Rule 2.2. If a potential offeror has any doubt about its obligations pursuant to the Irish Takeover Rules, it should contact its financial adviser(s) and, where applicable, it should also consult with the Irish Takeover Panel. This is an announcement under Rule 2.4 of the Irish Takeover Rules and is not an announcement of a firm intention by any party to make an offer under Rule 2.7 of the Irish Takeover Rules.
Seeking Alpha • Mar 28Mural Oncology: Phase 3 Clinical Trial Setback Undermines Company's Future ProspectsSummary Mural Oncology's stock plummeted 57% after halting the Phase 3 ARTISTRY-7 trial for nemvaleukin alfa, which failed to show significant overall survival benefits in PROC. The trial's failure delays any potential NDA submission, impacting the commercial viability of nemvaleukin alfa and raising concerns about its efficacy in other indications. Upcoming data from the Phase 2 ARTISTRY-6 trial for mucosal melanoma is crucial, but recent setbacks cast doubt on nemvaleukin alfa's overall prospects. Concerns about cash burn and potential dilutive capital raises further dampen our investment outlook, leading us to avoid investing in Mural Oncology. Read the full article on Seeking Alpha
공고 • Mar 25Mural Oncology plc Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with Keytruda®? (Pembrolizumab) in Patients with Platinum-Resistant Ovarian CancerMural Oncology plc announced that the ARTISTRY-7 phase 3 trial of nemvaleukin alfa in combination with Merck's (known as MSD outside the US and Canada) anti-PD-1 therapy, KEYTRUDA®? (pembrolizumab) versus investigator's choice chemotherapy in patients with platinum-resistant ovarian cancer (PROC) will not continue to final analysis and the company will cease development of nemvaleukin for PROC. In the pre-specified interim analysis conducted by the independent data monitoring committee, nemvaleukin in combination with pembrolizumab did not achieve a statistically significant improvement in overall survival versus investigator's choice chemotherapy alone and the company believes the study is highly unlikely to achieve success at the final analysis. Median overall survival was 10.1 months for patients treated with nemvaleukin in combination With pembrolizumab and 9.8 months for patients treated with investigator's choice chemotherapy (hazard ratio: 0.98). There has been a great deal of work across the industry in this immunologically cold tumor, yet there are still few treatment options that improve survival in this very difficult-to-treat tumor type. Nemvaleukin has a well characterized and favorable safety profile, both as a monotherapy and in combination with pembrolIZumab, with over 800 patients treated across the broader clinical program. Preliminary data readouts for less-frequent intravenous dosing of nemvaleukin in patients with cutaneous melanoma are expected in the second quarter of 2025 for cohort 3 of ARTISTRY-6 (monotherapy) and the second half of 2025 for cohort 4 of ARTISTRY-6 ("combination therapy), subject to patient enrollment.
공고 • Mar 12Mural Oncology plc has filed a Follow-on Equity Offering in the amount of $75 million.Mural Oncology plc has filed a Follow-on Equity Offering in the amount of $75 million. Security Name: Ordinary Shares Security Type: Common Stock Transaction Features: At the Market Offering
분석 기사 • Nov 26Here's Why We're Watching Mural Oncology's (NASDAQ:MURA) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...
공고 • Nov 13Mural Oncology plc Provides Update on Pipeline ProgressMural Oncology plc's late-stage trials of nemvaleukin alfa (nemvaleukin), an engineered fusion protein designed to leverage Interleukin-2’s (IL-2) antitumor effects while mitigating its hallmark toxicities, remain on track. The company shared new information related to study design, statistical assumptions, and study execution at a virtual Investor Day in September 2024, including: Completion of enrollment in ARTISTRY-7, the company’s potentially registrational phase 3 trial in platinum-resistant ovarian cancer (PROC), with a total of 456 patients enrolled. The study is comparing the combination of nemvaleukin and pembrolizumab versus investigator’s choice single agent chemotherapy. Mural expects to report interim overall survival (OS) results in late FIRST QUARTER OF or early SECOND QUARTER OF based on an analysis performed at approximately 75% of OS events. If the hazard ratio meets the bar for success (0.727, or a 27.3% reduction in the risk of death assuming exactly 215 OS events), the company plans to file a Biologics License Application (BLA) in 2025 subject to discussions with the U.S. Food and Drug Administration (FDA). The company expects to report final results in the second quarter of 2026. · Completion of enrollment in ARTISTRY-6, Cohort 2, the company’s potentially registrational phase 2 study of single agent nemvaleukin in patients with unresectable or metastatic mucosal melanoma, with 92 patients enrolled. Mural anticipates reporting top-line results from cohort 2 of ARTISTRY-6 in SECOND QUARTER Of 2025. The target response rate is 25%. Mural believes that in this rare and highly aggressive tumor with poor outcomes even in the first line setting, demonstrating durable responses with a response rate of 20-25% would be meaningful for patients, and would support a discussion with the FDA regarding a BLA submission and potential accelerated approval. Mural is also evaluating a less-frequent intravenous (LFIV) dose of nemvaleukin in patients with cutaneous melanoma in ARTISTRY-6, Cohort 3 (monotherapy) and Cohort 4 (combination with pembrolizumab). The company continues to expect preliminary data readouts in the monotherapy cohort in the first half of 2025, and in the combination cohort in the second half of 2025. Mural plans to nominate development candidates for its IL-18 and IL-12 programs by the end of 2024. The company expects to submit an Investigational New Drug (IND) Application for its IL-18 program to the FDA in fourth quarter of 2025.
공고 • Nov 08Mural Oncology Presents Clinical and Preclinical Data Across Its Pipeline At the 39Th Annual Meeting of the Society for Immunotherapy of CancerMural Oncology plc shared three poster presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer, taking place November 6-10, 2024 in Houston. Data presented from the ARTISTRY-3 clinical trial of Mural’s lead candidate, nemvaleukin alfa (nemvaleukin), showed tumor site-specific pharmacodynamic activity and immune activation in patients with ovarian cancer and mucosal melanoma. In addition, Mural presented preclinical data from its interleukin (IL)-12 and IL-18 programs that supported the company's unique protein engineering capabilities to overcome shortcomings associated with cytokines. Tumor microenvironment pharmacodynamic effect of nemvaleukin less frequent intravenous dosing in multiple solid tumors: results from the phase 1/2 ARTISTRY-3 study: Nemvaleukin is a novel, engineered fusion protein designed to leverage antitumor effects of the IL-2 pathway while mitigating the hallmark toxicities that have historically limited its use. ARTISTRY-3, a phase 1/2 study, evaluated less frequent intravenous dosing of nemvaleukin in advanced solid tumors. Paired biopsies were available from 8 patients across the three different dosing schedules of nemvaleukin. Collectively, LFIV nemvaleukin demonstrated tumor-site-specific pharmacodynamic activity and immune activation. Nemvaleukin treatment increased cytolytic NK and CD8 T cell densities in the tumor microenvironment. Density ratios of CD8 and NK cells relative to immune-suppressive Tregs were also favorable for the nemvaleukin LFIV regimen. The results were seen in biopsies from both mucosal melanoma and ovarian cancer tumors, supporting the hypothesis that nemvaleukin has the potential to recruit cytolytic effectors to poorly immunogenic tumor sites. Mural is currently running two late-stage, potentially registrational trials in platinum-resistant ovarian cancer (ARTISTRY-7) and mucosal melanoma (ARTISTRY-6, cohort 2), with data readouts expected in late Q1/early Second Quarter 2025 and Second Quarter 2025, respectively. Preclinical efficacy and immune activity of half-life extended IL-18 fusion proteins resistant to IL-18BP suppression. IL-18 is a potent immune-stimulating cytokine, but it is limited by IL-18 binding protein (IL-18BP), a secreted high-affinity decoy receptor that neutralizes IL-18, thus limiting its activity over time. Mural’s protein engineering aims to address the shortcomings of native IL-18 in two ways. First through the introduction of mutations designed to minimally impact the native structure while eliminating binding to IL-18BP. Secondly, by extending the half-life of IL-18BP via fusion to a protein scaffold to increase the cytokine’s exposure, allowing for sustained immune stimulation. In preclinical models, a weekly dosing regimen in mice provided durable immune responses and tumor growth inhibition. These mouse ortholog variants demonstrated resistance to IL-18BP and increased half-life, with durable expansion of immune-stimulating NK and CD8 T cells. These studies support pursuit of IND-enabling studies for first-in-human clinical trials. Mural plans to nominate a development candidate for its IL-18 program by the end of 2024 and intends to submit an Investigational New Drug (IND) Application to the FDA in Fourth Quarter 2025. Modulation of IL-12p70 exposure and activity following sequential administration of tumor targeted self-assembling split IL-12 subunits. IL-12p70 is a potent stimulator of the immune system with profound anti-tumor activity but very poor tolerability. Mural is developing an innovative approach to mitigate that toxicity by creating inactive split IL-12 subunits (IL-12p35 and IL-12p40) and assembling functional IL-12p70 predominantly in the tumor and tumor microenvironment. In murine models, increasing the interval time between subunit injections or reducing the dose level of the second subunit effectively modulated serum drug concentration while maintaining IL-12 levels in the tumor. Pharmacokinetics and pharmacodynamics were also assessed in non-human primates, where the inactive subunits were assembled and formed functional IL-12p70 in the periphery. Together, these data suggest Mural’s novel approach may unlock the potential of IL-12p70 as a therapeutic by mitigating the toxicity associated with systemic administration. Mural plans to nominate a development candidate for its IL-12 program by the end of 2024.
공고 • Sep 24Mural Oncology plc Appoints Sachiyo Minegishi to its Board of DirectorsMural Oncology plc announced the appointment of Sachiyo Minegishi to its board of directors, effective September 20, 2024. Ms. Minegishi will serve as Chair of the Audit Committee and will also be joining the company's Nominating and Corporate Governance Committee. With over 20 years of industry experience, Sachiyo brings a successful record of helping companies navigate through important clinical, financial, and corporate milestones. Sachiyo brings over two decades of biopharma experience, with a focus on corporate strategy, finance, development, and commercialization. She is currently the Chief Operating Officer at Rectify Pharmaceuticals, driving corporate and financing strategy to advance its lead program from discovery to clinical stage. Prior to Rectify, Sachiyo was Chief Financial Officer at Akouos Inc., where she led corporate finance and business development strategy and played a key role in the acquisition of the company by Eli Lilly. Before that, she was a Global Program Lead at bluebird bio, where she led a team to execute global development and commercialization strategy for a portfolio of gene therapies for sickle cell disease. Sachiyo has also held leadership roles that helped accelerate corporate growth at Human Genome Sciences, Genzyme, and Amgen.
공고 • Aug 01Mural Oncology plc Announces the Appointment of George Golumbeski to its Board of DirectorsMural Oncology plc announced the appointment of George Golumbeski, Ph.D., to its board of directors effective July 30. Dr. Golumbeski has extensive experience with strategic collaborations, M&A, in-licensing, out-licensing, and alliance management. He currently serves as a partner in DROIA Ventures, a specialist biotech investment firm focused on therapeutics for oncology and genetic disease. He previously served as President and Head of Corporate Development for GRAIL where he led corporate collaborations and served as an advisor to the CEO. Prior to GRAIL, Dr. Golumbeski was Executive Vice President of Business Development for Celgene (now a Bristol Myers Squibb company) where over his nine-year tenure he developed new models for corporate collaborations to drive corporate growth. He has also held leadership roles at Nabriva Therapeutics, Novartis Oncology, and Elan Biopharmaceuticals.
분석 기사 • Jul 17Here's Why We're A Bit Worried About Mural Oncology's (NASDAQ:MURA) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...
공고 • Jul 03Mural Oncology plc(NasdaqGM:MURA) dropped from Russell 3000 IndexMural Oncology plc(NasdaqGM:MURA) dropped from Russell 3000 Index
공고 • Apr 14Mural Oncology plc, Annual General Meeting, May 30, 2024Mural Oncology plc, Annual General Meeting, May 30, 2024, at 13:00 Coordinated Universal Time. Location: Arthur Cox LLP at Ten Earlsfort Terrace, Dublin 2, D02 T380 Ireland Agenda: To elect, by separate resolutions, the five director nominees named in this proxy statement to the board of directors, to serve until the Company’s 2025 annual general meeting; to ratify, in a non-binding advisory vote, the selection of PricewaterhouseCoopers LLP as the Company’s independent auditor for the fiscal year ending December 31, 2024 and to authorize, in a binding vote, the board of directors, acting through the audit committee, to set the independent auditor’s remuneration; and to consider and act on such business as may properly come before the AGM or any adjournment or postponement thereof.
분석 기사 • Mar 28We're Keeping An Eye On Mural Oncology's (NASDAQ:MURA) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Mar 04Recent Spin Mural Oncology At An Attractive Discount To Cash And Portfolio ValueSummary Mural Oncology trades at approximately $5, a material discount to cash holdings of over $16/share, as reported in November 2023. The pipeline of 3 major candidates of cytokine cancer therapies at different stages in clinical trials may offer material value if things go well. As a spin-off since November 2023, Mural may receive investor attention in 2024 as it starts to attend industry conferences and releases financial reports. Still, this is a risky and illiquid biotech small cap that could go to zero if trial results are poor or for other reasons. Read the full article on Seeking Alpha
공고 • Jan 09Mural Oncology plc Announces Enhancements to Late-Stage Clinical TrialsMural Oncology plc announced strategic changes to its ARTISTRY-6 and ARTISTRY-7 clinical trials designed to generate more meaningful clinical data for these late-stage, potentially registrational trials of nemvaleukin. These changes are as follows: Cohort 2 of ARTISTRY-6 is a potentially registrational, phase 2 trial evaluating nemvaleukin as a monotherapy in mucosal melanoma patients. Together have been thinking critically about the best ways to deliver treatments to patients who desperately need them. The company believe expanding patient enrollment in both potentially registrational trials, as well as shifting the primary endpoint of the ARISTRY-7 trial, may result in more meaningful clinical data. Now led by an experienced and highly accomplished oncology-focused executive team and board of directors, the company is leveraging its core competencies in immune cell modulation and protein engineering. Mural's lead product candidate, nemvaleukin, is being developed to treat a wide range of solid tumors. Mural is also advancing engineered therapies targeting interleukin-18 and interleukin-12, with plans to nominate development candidates for each program in 2024. The Company's cash resources of $275 million, as of November 15, 2023, are expected to fund its operations into fourth quarter 2025.